{"id":251687,"date":"2024-01-10T00:00:00","date_gmt":"2024-01-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidid0053-biopharma-hepatitis-b-virus-vaccine-epidemiology-mature\/"},"modified":"2026-03-31T10:31:12","modified_gmt":"2026-03-31T10:31:12","slug":"epidid0053-biopharma-hepatitis-b-virus-vaccine-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0053-biopharma-hepatitis-b-virus-vaccine-epidemiology-mature-markets\/","title":{"rendered":"Hepatitis B Virus Vaccine &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of the hepatitis B virus (<abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr>) vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the population recommended to receive the <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine-eligible population over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts two <abbr data-abbreviation-entity=\"5636\" title=\"hepatitis B virus\">HBV<\/abbr> vaccine patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Vaccine-eligible population.<\/li>\n<li>Population newly eligible for the vaccine.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251687","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-pain","biopharma-therapy-areas-hepatitis-b-virus","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251687\/revisions"}],"predecessor-version":[{"id":293156,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251687\/revisions\/293156"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}